112 related articles for article (PubMed ID: 34976157)
1. Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuria.
Kimura M; Usami E; Teramachi H; Yoshimura T
Oncol Lett; 2022 Feb; 23(2):45. PubMed ID: 34976157
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis.
Kanbayashi Y; Ishikawa T; Tabuchi Y; Sakaguchi K; Ouchi Y; Otsuji E; Takayama K; Taguchi T
Sci Rep; 2020 Feb; 10(1):2011. PubMed ID: 32029849
[TBL] [Abstract][Full Text] [Related]
3. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
4. [Proteinuria in Patients with Gastric Cancer Treated with Ramucirumab].
Kimura Y; Mikami J; Makari Y; Fujii C; Hiraki Y; Imano M; Fujita J; Yasuda T
Gan To Kagaku Ryoho; 2019 Feb; 46(2):245-249. PubMed ID: 30914527
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis.
Hirai T; Shuji Y; Takiyama M; Hanada K; Itoh T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):195-202. PubMed ID: 31119376
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
7. [Urine Protein/Creatinine Ratio Measurement Is Useful to Continue Anti-Angiogenic Agent Treatment].
Saito Y; Kitagawa K; Sato J; Yamamoto H; Watanabe M; Masubuchi M
Gan To Kagaku Ryoho; 2019 Nov; 46(11):1741-1745. PubMed ID: 31748484
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
[TBL] [Abstract][Full Text] [Related]
9. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
[TBL] [Abstract][Full Text] [Related]
10. [Incidence of Proteinuria among Japanese Colorectal Cancer Patients after Receiving Ramucirumab-Cohort Study Using Claim Database].
Kobayashi T; Tanizawa Y; Nagaoka S; Chen Y; Kitagawa N; Muto M; Piao Y
Gan To Kagaku Ryoho; 2020 Jun; 47(6):917-922. PubMed ID: 32541168
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study.
Dote S; Yamaguchi D; Hira D; Noda S; Kobayashi Y; Terada T
Biol Pharm Bull; 2020; 43(4):752-756. PubMed ID: 32238718
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer.
Uehata N; Kouzu K; Tsujimoto H; Sugasawa H; Wakamatsu K; Kishi Y; Ueno H
Surg Case Rep; 2021 Apr; 7(1):97. PubMed ID: 33876326
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
17. A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings.
Nakano Y; Kumagai J; Nagahama K; Fujisawa H
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33653851
[TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
